Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new?
The article provides the latest data of our foreign colleagues on the potential use and dosing regimen of lenvatinib in real clinical practice. Since adverse events during lenvatinib treatment often lead to dose reduction or its discontinuation and, as a consequence, to a decrease in progression-fre...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2024-12-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/1023 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689268906098688 |
|---|---|
| author | E. V. Borodavina S. I. Kutukova A. Yu. Shurinov V. V. Krylov |
| author_facet | E. V. Borodavina S. I. Kutukova A. Yu. Shurinov V. V. Krylov |
| author_sort | E. V. Borodavina |
| collection | DOAJ |
| description | The article provides the latest data of our foreign colleagues on the potential use and dosing regimen of lenvatinib in real clinical practice. Since adverse events during lenvatinib treatment often lead to dose reduction or its discontinuation and, as a consequence, to a decrease in progression-free survival and overall survival benefit, optimization of lenvatinib dosing regimen is of great interest to experts from different countries. Today, so-called drug holidays are being actively studied as a possible option to reduce lenvatinib toxicity, without loss of efficacy in patients with advanced radioiodine-refractory differentiated thyroid cancer. In addition, given the small number of therapeutic options for this patient group, their low efficacy and poor availability of tumor mutation profiling and effect on target genes, a question arises: “Is it possible to benefit in progression-free survival and overall survival with lenvatinib rechallenge after disease progression in the 2nd or 3rd treatment lines?” |
| format | Article |
| id | doaj-art-f4dfe2b7b2cb4a8aad2af0f1bfec2ef6 |
| institution | DOAJ |
| issn | 2222-1468 2411-4634 |
| language | Russian |
| publishDate | 2024-12-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли головы и шеи |
| spelling | doaj-art-f4dfe2b7b2cb4a8aad2af0f1bfec2ef62025-08-20T03:21:42ZrusABV-pressОпухоли головы и шеи2222-14682411-46342024-12-01144425010.17650/2222-1468-2024-14-4-42-50615Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new?E. V. Borodavina0S. I. Kutukova1A. Yu. Shurinov2V. V. Krylov3A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre, Ministry of Health of RussiaCity Clinical Oncological Dispensary; Pavlov University, Ministry of Health of RussiaA.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre, Ministry of Health of RussiaA.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Centre, Ministry of Health of RussiaThe article provides the latest data of our foreign colleagues on the potential use and dosing regimen of lenvatinib in real clinical practice. Since adverse events during lenvatinib treatment often lead to dose reduction or its discontinuation and, as a consequence, to a decrease in progression-free survival and overall survival benefit, optimization of lenvatinib dosing regimen is of great interest to experts from different countries. Today, so-called drug holidays are being actively studied as a possible option to reduce lenvatinib toxicity, without loss of efficacy in patients with advanced radioiodine-refractory differentiated thyroid cancer. In addition, given the small number of therapeutic options for this patient group, their low efficacy and poor availability of tumor mutation profiling and effect on target genes, a question arises: “Is it possible to benefit in progression-free survival and overall survival with lenvatinib rechallenge after disease progression in the 2nd or 3rd treatment lines?”https://ogsh.abvpress.ru/jour/article/view/1023lenvatinibradioiodine-refractory differentiated thyroid canceradverse eventsprogression-free survivaloverall survivaldrug holidays |
| spellingShingle | E. V. Borodavina S. I. Kutukova A. Yu. Shurinov V. V. Krylov Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new? Опухоли головы и шеи lenvatinib radioiodine-refractory differentiated thyroid cancer adverse events progression-free survival overall survival drug holidays |
| title | Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new? |
| title_full | Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new? |
| title_fullStr | Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new? |
| title_full_unstemmed | Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new? |
| title_short | Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new? |
| title_sort | lenvatinib in advanced radioiodine refractory differentiated thyroid cancer what s new |
| topic | lenvatinib radioiodine-refractory differentiated thyroid cancer adverse events progression-free survival overall survival drug holidays |
| url | https://ogsh.abvpress.ru/jour/article/view/1023 |
| work_keys_str_mv | AT evborodavina lenvatinibinadvancedradioiodinerefractorydifferentiatedthyroidcancerwhatsnew AT sikutukova lenvatinibinadvancedradioiodinerefractorydifferentiatedthyroidcancerwhatsnew AT ayushurinov lenvatinibinadvancedradioiodinerefractorydifferentiatedthyroidcancerwhatsnew AT vvkrylov lenvatinibinadvancedradioiodinerefractorydifferentiatedthyroidcancerwhatsnew |